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The blood–brain barrier (BBB) is a biological ﬁrewall that carefully regulates the cerebral micro-
environment by acting as a physical, metabolic and transport barrier. This selectively permeable interface
was modelled using the immortalised human cerebral microvascular endothelial cell line (hCMEC/D3) to
investigate interactions with the cationic amino acid (CAA) L-arginine, the precursor for nitric oxide (NO),
and with asymmetric dimethylarginine (ADMA), an endogenously derived analogue of L-arginine that
potently inhibits NO production. The transport mechanisms utilised by L-arginine are known but they are
not fully understood for ADMA, particularly at the BBB. This is of clinical signiﬁcance giving the emerging
role of ADMA in many brain and cerebrovascular diseases and its potential as a therapeutic target. We
discovered that high concentrations of ADMA could induce endothelial dysfunction in the hCMEC/D3s
BBB permeability model, leading to an increase in paracellular permeability to the paracellular marker
FITC-dextran (40 kDa). We also investigated interactions of ADMA with a variety of transport mechan-
isms, comparing the data with L-arginine interactions. Both molecules are able to utilise the CAA
transport system yþ . Furthermore, the expression of CAT-1, the best known protein from this group, was
conﬁrmed in the hCMEC/D3s. It is likely that inﬂux systems, such as yþL and b0,þ , have an important
physiological role in ADMA transport at the BBB. These data are not only important with regards to the
brain, but apply to other microvascular endothelia where ADMA is a major area of investigation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
ADMA is an endogenously derived analogue of the CAA, L-ar-
ginine, and is produced during routine proteolysis of methylated
arginine residues on proteins by a group of enzymes called pro-
tein-arginine methyltransferases (PRMTs) (Palm et al., 2007).
Whereas L-arginine is a substrate for nitric oxide synthases (NOS)
which catalyse the oxidation of L-arginine to L-citrulline and nitric
oxide (NO) (using NADPH and O2 as co-substrates), ADMA acts as ar B.V. This is an open access articl
e; BBB, blood-brain barrier;
transporter 1; DDAH, NG, NG-
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as).potent inhibitor of NO production and inhibits all NOS isoforms by
competing with L-arginine for the NOS binding site (Vallance et al.,
1992; Leiper and Vallance, 1999; Tran et al., 2003; Siroen et al.,
2006; Kittel and Maas, 2014).
Because of its potency as an inhibitor of NO, ADMA has been
implicated in a wide variety of pathophysiological conditions
throughout the body including hypercholesterolemia, hyperho-
mocysteinemia and hypertriglyceridemia (Boger et al., 1998;
Lundman et al., 2001; Sydow et al., 2003); a host of cardiovascular
conditions (Boger, 2003, 2004; Perticone et al., 2005); neuroin-
ﬂammatory and neurodegenerative diseases including Alzheimer's
disease (Selley, 2003; Arlt et al., 2008); cerebrovascular diseases
such as stroke (Yoo and Lee, 2001; Brouns et al., 2009); micro-
angiopathy-related cerebral damage (Notsu et al., 2009), and re-
cently, intrauterine foetal growth restriction (Laskowska et al.,
2014).
Given these disease implications, it is somewhat surprising that
the basic cellular transport mechanisms of ADMA remain under-
studied. The main reason is the structural similarity of ADMA to L-e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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chanisms, although data directly looking at ADMA membrane
transport in vascular endothelial cells is lacking. Recent work by
Strobel et al. showed that ADMA is able to utilise CAT2 (2A and
2B), organic cation transporter 2 (OCT2) and multidrug and toxin
exclusion protein 1 (MATE1), albeit in a HEK239 cell model over-
expressing these transporters and not vascular endothelial cells.
They showed that the transport kinetics of CAT2A, CAT2B, and
OCT2 indicate a low afﬁnity, high capacity transport for ADMA
(Strobel et al., 2013). Interestingly, a study by Ohtsuki et al. (2013)
could not detect the expression of MATE1 and OCT2 membrane
proteins in hCMEC/D3 cells. In addition, the transport of ADMA at
the blood-brain barrier (BBB) has yet to be investigated despite the
emerging role of the molecule in brain and cerebrovascular
pathologies and the importance of the BBB as a dynamic interface
between the brain and blood (Abbott et al., 2006). The transport
mechanisms for L-arginine have been described at the bovine BBB:
the principle L-arginine transporters here are CAT1, CAT2B and
CAT3, which are all members of system yþ (O'kane et al., 2006).
Interestingly, other data have implicated the system yþ large
neutral amino acid transporters (yþLAT) yþLAT1 and yþLAT2 in
human in vitro BBB models (Carl et al., 2010).
One of the aims of this study was to test the hypothesis that
ADMA has a similar transport proﬁle to L-arginine in human brain
endothelial cells. A major issue with BBB research (as with most
other ﬁelds) is that the wide variety of models in use can make it
difﬁcult to relate and compare data, particularly between species.
For example, much of the CAA transport work has utilised single
cloned transporters expressed in Xenopus laevis oocytes and this is
unlikely to give an accurate indication of the situation in mam-
malian systems where multiple transporters are present.
The hCMEC/D3 cell line is a commercially available, easily
grown and transferable population of human microvascular CEC
that stably maintains a normal BBB phenotype. These include ex-
pression of tight junction proteins, polarized expression of multi-
ple ABC/SLC transporters and restrictive permeability. It has been
used in over 100 different published studies of the BBB (Weksler
et al., 2013).
We thus compared the transport of ADMA and L-arginine in an
accumulation model format using this well-established hCMEC/D3
human BBB model (Watson et al., 2012).
We also investigated the association between ADMA con-
centration and endothelial dysfunction. Such associations have
been made in a variety of pathological conditions including
chronic heart failure, renal failure, and a variety of diabetic com-
plications such as renin-angiotensin system mediated diabetic
retinopathy (Boger et al., 1998; Leiper et al., 2007, Chen et al.,
2009; Chen et al., 2011). ADMA and its metabolising enzyme, NG,
NG-dimethylarginine dimethylaminohydrolase (DDAH), have also
recently been implicated as regulators of pulmonary endothelial
barrier function through the modulation of small guanosine tri-
phosphatases (GTPases). This has been demonstrated in both in
vitro and in vivowith mouse models (Wojciak-Stothard et al., 2007,
2009). ADMA has also been heavily implicated in the production of
reactive oxygen species (ROS) via uncoupling of endothelial NOS,
causing the enzyme to produce superoxides and not NO (Sydow
and Munzel, 2003; Chen et al., 2011).
One of the hallmarks of endothelial dysfunction is an increase
in leakiness via the paracellular route. Whereas the above-
mentioned studies investigated the effects of ADMA on non-cer-
ebral vasculature, no group has yet studied ADMA and BBB dys-
function. This is of particular importance because not only is BBB
integrity paramount for maintaining homeostasis within the cer-
ebral microenvironment, but ADMA has also been implicated in
endothelial dysfunction in brain and cerebrovascular disorders
such as ischemic stroke (Scherbakov et al., 2012).Therefore, we investigated the effects of ADMA on the integrity
of the human BBB in vitro using the hCMEC/D3 cell line in a
paracellular permeability model format. Other in vitro studies have
only investigated ADMA in cerebral endothelial dysfunction at
high concentrations, so we decided to look at a range covering the
physiological and pathophysiological concentrations of ADMA. We
hypothesised that increased concentrations of ADMA would lead
to increased BBB permeability, especially at concentrations in line
with previous non-BBB studies, but did not rule out the possibility
that lower concentrations may also induce permeability changes.2. Results
2.1. Octanol-saline partition coefﬁcient (OSPC) of [3H]L-arginine and
[3H]ADMA
An OSPC was performed on all radiolabelled compounds to
assess their relative lipophilicity which would give an indication of
their potential to cross cell membranes by passive diffusion and
accumulate in the cells. The mean OSPC values for [3H]L-arginine
(MW 174.2 g/mol) and [3H]ADMA (MW 202.25 g/mol) were
0.001570.0002 and 0.002370.0001 respectively (n¼3). These
values are statistically signiﬁcantly different from each other
(po0.01). Our group previously performed OSPC analysis on [14C]
sucrose (MW 342.3 g/mol; n¼3) obtaining a mean value of
0.000470.00001, which was signiﬁcantly lower when compared
to [3H]L-arginine and [3H]ADMA (both po0.001).
2.2. [3H]L-arginine and [3H]ADMA accumulation comparison
The values for [14C]sucrose and protein corrected [3H]L-argi-
nine and [3H]ADMA accumulation in the hCMEC/D3 cells are
shown in Figs. 1 and 2, respectively. The accumulation of [3H]
ADMA (38 nM) in the hCMEC/D3 cells increased in a time-de-
pendent manner from a Vd of 13.5870.66 μl/mg protein at 1 min,
to a Vd of 61.2472.92 μl/mg protein at 30 min. In a similar
manner, the accumulation of [3H]L-arginine (7 nM) increased in a
time-dependent manner from a Vd of 33.7571.70 μl/mg protein
at 1 min, to a Vd of 106.7971.73 μl/mg protein at 30 min. At all
time points, [3H]L-arginine Vd values were signiﬁcantly higher
than those for [3H]ADMA (po0.001 at all time points).
2.3. Accumulation of [3H]L-arginine – role of CAA transporters
To assess the roles of CAA transporters on the transport and
accumulation of [3H]L-arginine in the hCMEC/D3s, 100 mM un-
labelled L-arginine, 20 mM L-homoarginine and 100 mM L-leucine
were added individually to the accumulation buffer alongside [3H]
L-arginine and [14C]sucrose, and compared to appropriate controls.
The control Vd values (μl/mg of protein) for [3H]L-arginine
were 33.75 at 1 min, 57.99 at 2.5 min, 79.84 at 5 min, 100.30 at
20 min and 106.79 at 30 min. The addition of 100 mM unlabelled L-
arginine caused a marked decrease in the accumulation of [3H]L-
arginine (po0.001), with an average percentage decrease across
the time points of 73% (Fig. 1A). Accumulation was almost com-
pletely inhibited (with an approximate decrease of 98% observed
across all time points) with the addition of 20 mM L-homoarginine
(po0.001). The addition of 100 mM L-leucine to the accumulation
buffer caused no signiﬁcant changes in [3H]L-arginine
accumulation.
To investigate the possible competitive effect of ADMA on the
inﬂux and accumulation of [3H]L-arginine, 0.5 mM, 3 mM, and
500 mM unlabelled ADMA were added individually to the accu-
mulation buffer. When 0.5 mM and 3 mM ADMA was added, there
were no signiﬁcant differences in accumulation when compared to
Fig. 1. Accumulation of [3H]L-arginine in hCMEC/D3 cells. (A) To understand the
roles CAA transporters played in the transport and subsequent accumulation of [3H]
L-arginine, self-inhibition and the addition of known AA transporter interacting
molecules was performed in an accumulation model using conﬂuent hCMEC/D3s.
Control L-arginine values were compared to treatments. ***po0.001. (B) To in-
vestigate the competitive effects of unlabelled ADMA on [3H]L-arginine accumu-
lation, 0.5 mM, 3 mM and 500 mM ADMA were added individually to accumulation
buffer. ***po0.001. All [3H]L-arginine data are corrected for [14C]sucrose and
protein content (with [14C]sucrose corrected for protein only) and expressed as
means7SEM, n¼6 plates with 6 replicates per plate.
Fig. 2. Accumulation of [3H]ADMA in hCMEC/D3 cells. (A) To investigate self and
competitive inhibition on [3H]ADMA transport and accumulation, 0.5 mM, 3 mM and
500 mM unlabelled ADMA and 100 mM L-arginine were added individually to the
accumulation buffer. *po0.05,***po0.001. (B) To understand the roles CAA
transporters played in the transport and subsequent accumulation of [3H]ADMA,
the addition of known AA transporter interacting molecules was performed in an
accumulation model using conﬂuent hCMEC/D3s. *po0.05,**po0.01. All [3H]
ADMA data are corrected for protein content and [14C]sucrose (with [14C]sucrose
corrected for protein only) and expressed as means7SEM, n¼5 (A) or 4–6
(B) plates with 6 replicates per plate.
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arginine accumulation of 83% across the time points was seen with
the addition of 500 mM ADMA (po0.001) when compared to
controls (Fig. 1B).
2.4. Accumulation of [3H]ADMA – role of CAA transporters
To elucidate the transport mechanisms utilised by ADMA in the
hCMEC/D3s, a series of accumulation experiments similar to those
used for [3H]L-arginine were designed to assess the effects of self-
inhibition, competitive inhibition and CAA transporters on the
transport and resulting accumulation of [3H]ADMA and [14C]
sucrose.
The control Vd values (μl/mg of protein) for [3H]ADMA were
13.58 at 1 min, 25.36 at 2.5 min, 41.32 at 5 min, 58.76 at 20 min
and 61.24 at 30 min. To investigate self- and cross-inhibition of
[3H]ADMA transport and accumulation, 0.5 mM, 3 mM and 500 mM
unlabelled ADMA as well as 100 mM L-arginine were added in-
dividually to the accumulation buffer which also contained [3H]
ADMA and [14C]sucrose. 0.5 mM ADMA caused a decrease in the
accumulation of [3H]ADMA, but this failed to attain statisticalsigniﬁcance. In contrast, 3 mM caused signiﬁcant decreases in [3H]
ADMA accumulation at 20 min and 30 min (po0.05, Fig. 2A). A
decrease in [3H]ADMA accumulation of 87% was observed across
all time points on the addition of 500 mM ADMA (po0.001).
100 mM L-arginine also caused an average decrease of 36% across
time points, but statistical signiﬁcance was only apparent after
5 min, 20 min and 30 min (po0.05 for each comparison).
The inﬂuence of CAA transporters on [3H]ADMA and [14C]su-
crose was initially determined using 20 mM L-homoarginine. The
addition of 20 mM L-homoarginine caused a large decrease in
accumulation of [3H]ADMA at all time points, which gained higher
signiﬁcance as the incubation time increased (Fig. 2B). The per-
centage decreases in Vd induced by L-homoarginine were 47% for
1 min, 64% for 2.5 min, 75% for 5 min, 8%1 for 20 min and 76% for
30 min. The addition of 100 mM L-leucine saw signiﬁcant decreases
in [3H]ADMA accumulation from 5 min (21% decrease), to 20 min
(40% decrease) and 30 min (38% decrease, all po0.05).
Fig. 3. Expression of CAT-1 in hCMEC/D3 cells. (A) SDS-PAGE and WB analysis revealed CAT-1 expression in hCMEC/D3 (P28) and wild type MCF7 whole cell lysate lysed in
TGN lysis buffer, as described in Section 4.9. (B) CAT-1 expression was also demonstrated by IF performed with hCMEC/D3 cells (P28) grown on rat tail collagen type 1-coated
coverslips, ﬁxed with 4% formaldehyde and stained with primary and secondary antibody, and viewed at 63 with oil emersion using a Zeiss LSM710 confocal microscope
and image analysis software Zen 2009 as described in Section 4.9. This localization appears to be on the membrane, similar to the results seen in other studies (Closs et al.,
2004). Scale bar, 10 mm. Cell nuclei were counterstained with 1 mg/ml DAPI. For negative staining, cells were stained with secondary antibody only along with DAPI (inserts).
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Sucrose was used throughout the transport assays as a marker
for unspeciﬁc binding and extracellular space. There were no
signiﬁcant changes in the accumulation of [14C]sucrose from
baseline values in any transport studies in this investigation (data
not shown).
2.6. Expression of CAT-1 in hCMEC/D3 cells
Rabbit anti-human CAT-1 primary antibody was used with goat
anti-rabbit HRP conjugated secondary antibody for WB detection
of CAT-1 in the TGN lysed hCMEC/D3s and wt MCF7 whole cell
lysates. The blot revealed expression of CAT-1 of the expected size
of 60–70 kDa (Fig. 3A) according to the antibody manufacturer and
previously published studies (Battisti et al., 2012; Mun et al., 2011;
Diaz-Perez et al., 2012; Strobel et al., 2012).
CAT-1 expression was also observed with IF and subsequent
confocal microscopy in the hCMEC/D3s (Fig. 3B) using rabbit anti-
human CAT-1 primary antibody and goat anti-rabbit Alexa Fluor
488 conjugated secondary antibody. It showed typical membrane/
cytoskeletal-like patterning (Closs et al., 2004).
2.7. Effects of ADMA on hCMEC/D3 permeability to 40 kDa FITC-
dextran
To investigate the impact of ADMA on the integrity of the
hCMEC/D3s, cells grown on transwell ﬁlters for 8–10 days were
incubated with a range of ADMA concentrations for 24 hr before
permeability assays with FITC-Dex were performed (Fig. 4A). The
concentrations of ADMA used reﬂected the physiological (0.5 mM),
pathophysiological (3 mM) human plasma ranges, as well as 10 mMand 100 mM (values used in published in vitro studies by other
research groups). 500 mM was used as an extreme reference point.
There were no signiﬁcant differences between the 0.5 mM, 3 mM
and 10 mM ADMA treatments between each other or control cells
(untreated) on the permeability of the hCMEC/D3 cells to FITC-
Dex. However, the incubation of the cells with 100 mM ADMA saw
a signiﬁcant increase in the permeability to FITC-Dex when com-
pared to controls (52% increase, po0.05) and 10 mM ADMA (53%
increase, po0.05).
Incubation with 50 mM ADMA caused a signiﬁcant increase in
permeability when compared to the 0.5 mM, 3 mM, 10 mM ADMA
treatments and controls (po0.01 in all instances); 84% increase
versus controls; 67% increase versus 0.5 mM ADMA; 73% increase
when compared to 3 mM; and an 85% increase compared to 10 mM
ADMA. There were no signiﬁcant differences in permeability
coefﬁcients between 100 mM and 500 mM ADMA treatments.2.8. Effects of L-NIO and TNF-α plus IFN-γ on hCMEC/D3 perme-
ability to 40 kDa FITC-dextran
The potent eNOS inhibitor L-NIO and the pro-inﬂammatory
cytokines TNF-α and IFN-γ were incubated with the hCMEC/D3s
grown on transwell ﬁlter inserts, to investigate their effects on
permeability to 40 kDa FITC-Dex.
When compared to controls, 5 mM L-NIO caused no signiﬁcant
changes in permeability (Fig. 4B). When incubated with 5 ng/ml
TNF-α and 5 ng/ml IFN-γ, permeability of hCMEC/D3 cells to FITC-
Dex signiﬁcantly increased when compared to controls (po0.001)
and L-NIO (po0.001). The percentage increases were 200% com-
pared control and 204% compared to L-NIO.
Fig. 4. Impact of ADMA, L-NIO, TNF-α and IFN-γ on hCMEC/D3 permeability to
40 kDa FITC-Dex. (A) Conﬂuent monolayers of hCMEC/D3 cells, grown on rat tail
collagen type 1-coated transwell ﬁlter inserts for 8–10 days, were incubated for 24
hr with a range of ADMA concentrations and their permeability to 40 kDa FITC-Dex
was investigated and compared to control (untreated) cells. (B) Conﬂuent mono-
layers of hCMEC/D3 cells, grown on rat tail collagen type 1-coated transwell ﬁlter
inserts for 8–10 days, were incubated for 24 h with either 5 mM L-NIO or 5 ng/ml
TNF-α & 5 ng/ml IFN-γ, and their permeability to 40 kDa FITC-Dex was investigated
and compared to control (untreated) cells. Data represent means7SEM from 12 to
15 transwell ﬁlter inserts per treatment. Data analysed with one-way ANOVA and
Bonferroni’s post hoc test.
Fig. 5. Cytotoxicity of permeability treatments on hCMEC/D3s. The pharmacolo-
gical treatments used were assessed for any cytotoxic potential using an MTT assay
with conﬂuent monolayers of hCMEC/D3 cells in 96 well plates, grown in perme-
ability medium as described in Section 4.3. The results are expressed as percentage
viability7SEM and compared to control untreated cells, which were incubated in
permeability medium alone. TNF-α and IFN-γ were used together at 5 ng/ml each.
N¼3 plates, with 6 replicates per plate.
Fig. 6. Formation of ROS in hCMEC/D3 cells. hCMEC/D3 cells were treated with
increasing doses of ADMA for 24 h before assessment of ROS levels with DHE. As a
positive control, some wells were treated with 300 mM H2O2 alone for 30 min be-
fore measuring ROS levels. ADMA treatment had no signiﬁcant effect on ROS levels
in hCMEC/D3 cells, while exposure to H2O2 signiﬁcantly increased ROS in these
cells (one way ANOVA,*po0.05).
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No cytotoxic effects were detected using an MTT assay
throughout the experiments, except in the 24-h incubations used
in the transwell permeability experiments. Here the ADMA con-
centrations of 100 mM and 500 mM and 5 ng/ml TNF-α and 5 ng/ml
IFN-γ caused signiﬁcant reductions in cell viability (po0.05,
po0.01 and po0.001 respectively for treatments, Fig. 5).
2.10. Generation of ROS
The effect of ADMA on the generation of ROS was assessed in
the cells by measuring DHE ﬂuorescence after 24 h (ADMA) or30 min (H2O2) exposure, as described. DHE ﬂuorescence indicates
that exposure to ADMA did not increase ROS in these cells after a
24 h exposure at any of the doses tested (Fig. 6). However, 30 min
exposure to 300 mM H2O2 did signiﬁcantly increase ROS levels in
these cells (one way ANOVA, F6,140¼3.4662, po0.05).
2.11. Expression of eNOS and DDAH-1 in hCMEC/D3 cells
To look for expression of the ADMA interacting enzymes eNOS
and DDAH-1, SDS-PAGE and WBs were performed on hCMEC/D3
whole cell lysate, with GAPDH as a loading control and HUVEC
whole cell lysate used as positive controls. Blots at the expected
sizes (140 kDa for eNOS and 37 kDa for DDAH-1) were visible in
both the hCMEC/D3s and HUVEC positive controls (data not
shown).
3. Discussion
The idea that ADMA plays roles in endothelial dysfunction and
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lating in vitro and in vivo data from a variety of studies on different
body regions. ADMA is also a ‘hot-topic’ of investigation in vas-
cular biology research as it is a potent inhibitor of NO production
(Teerlink et al., 2009). ADMA is therefore of acute interest to re-
searchers investigating specialised vasculature such as the BBB,
particularly given that NO appears to have functional and protec-
tive roles as well as deleterious effects depending on its source and
the state of brain and cerebrovascular health (Thiel and Audus,
2001). Furthermore, ADMA has been implicated as not only a
marker, but also a mediator of cerebral perfusion and cognitive
impairment in microangiopathy-related cerebral damage (Kiel-
stein and Kielstein, 2009, Notsu et al., 2009). In acute stroke, in-
creased levels of ADMA have been observed in transient ischemic
attacks and cardioembolic infarctions (Wanby et al., 2006; Scher-
bakov et al., 2012) and ADMA levels in human CSF are believed to
be correlated with stroke severity (Brouns et al., 2009). ADMA has
also been implicated as a mediator of cerebral vascular tone, by
increasing arterial stiffness and decreasing cerebral blood ﬂow
independent of blood pressure (Kielstein et al., 2006). We in-
vestigated the effects of ADMA on the human BBB by using the
hCMEC/D3 in vitro BBB model, attempting to shed light on the
basic mechanisms expressed at this interface for ADMA.
We ﬁrst determined the OSPC values for the molecules under
investigation, giving us an indication of their lipophilicity and
passive membrane penetration without the inﬂuence of trans-
porters. The data indicated that both [3H]L-arginine and [3H]
ADMA had high hydrophilicity, with [3H]L-arginine having statis-
tically lower lipophilicity than [3H]ADMA. Both molecules had
higher lipophilic characteristics than [14C]sucrose, which is used as
an impermeant paracellular permeability and non-speciﬁc binding
marker in BBB studies. Therefore without the inﬂuence of trans-
porters, the intracellular accumulation of [3H]L-arginine and [3H]
ADMA should be low, but in a range similar or higher than [14C]
sucrose. Interestingly, [3H]arginine accumulation into hCMEC/D3
cells was higher than that achieved for [3H]ADMA suggesting the
inﬂuence of transporters.
Our investigations into the interactions between ADMA and
CAA transporters is novel with respect to the human BBB and has
wider implications due to the ubiquitous expression of CAA
transporters throughout the body. Little is known about ADMA
transport in vitro, especially in human endothelial cell systems
mainly due to the assumption that it uses system yþ transporters
like L-arginine (Teerlink et al., 2009). The only exceptions are
studies using human embryonic kidney epithelial cells stably
overexpressing CAT1 and CAT2 (2A & 2B) (Strobel et al., 2012,
2013).
We showed that the accumulation of [3H]L-arginine (7nM) was
decreased signiﬁcantly with the addition of 100 mM L-arginine,
which is representative of the normal adult L-arginine plasma
concentration (Moller et al., 1979, 1983). This suggests transport
competition for inﬂux transport mechanisms. Further experiments
with 20 mM L-homoarginine revealed that the inﬂux mechanisms
utilised was a member of system yþ , with an almost complete halt
of accumulation seen within 1 min (98% decrease) which persisted
for the rest of the 30 min time period observed. L-homoarginine is
known to competitively inhibit system yþ (White, 1985) and the
concentration used here was based on that of a previous in vitro
BBB study using bovine BMECs (O'kane et al., 2006). The impact of
L-homoarginine here also dismisses the L-arginine transport roles
of other CAA inﬂux mechanisms such as system yþL transporters
in the transport of L-arginine at the human BBB (O'kane et al.,
2006). The lack of inhibition of L-arginine transport upon addition
of the NAA leucine at physiological concentrations also supported
the ﬁnding that system yþ appears to be the physiologically re-
levant transport system used by L-arginine in these cells.These data were not unexpected, as it has been well established
that system yþ is the principle CAA transport system in mammals.
Which CAT isoform is responsible remains undetermined, but as
CAT-1 is well characterised at the BBB, it remains likely that this
protein is involved. A recent study investigating ADMA transport
showed that CAT2A, CAT2B, and OCT2 indicate a low afﬁnity, high
capacity transport for ADMA in a human kidney cell line over-
expressing these transport proteins (Strobel et al., 2013), sug-
gesting that these are also involved in BBB transport of ADMA. The
expression of CAT-1 was conﬁrmed in hCMEC/D3s cells through
WB of whole cell lysates and through IF analysis showing a
staining pattern that suggests typical membrane localization and
corresponds with previous studies on CAT-1 activity (Closs et al.,
2004) as previously demonstrated in pulmonary artery endothelial
cells (Mcdonald et al., 1997; Zharikov et al., 2001). We are conse-
quently the ﬁrst to report expression of CAT-1 in hCMEC/D3 cells,
although further research is needed to further conﬁrm the mem-
brane localization of CAT-1 in these cells.
The addition of 500 mM unlabelled ADMA signiﬁcantly reduced
accumulation of [3H]L-arginine. In one respect, this ﬁnding pro-
vides evidence that both molecules can interact with the same
transport mechanisms for entry to the cells. On the other hand,
although a marked decrease in accumulation was observed, the
concentration of 500 mM ADMA is supraphysiological and is not
likely to be reached in the body. Importantly, when physiological
(0.5 mM) and pathophysiological (3 mM) concentrations of ADMA
were used, no signiﬁcant change in [3H]arginine accumulation was
observed. A similar ﬁnding has been previously reported using
human dermal microvascular endothelial cells where 2.5 mM and
10 mM ADMA did not signiﬁcantly reduce L-arginine accumulation
(Xiao et al., 2001).
When investigating the accumulation of [3H]ADMA, self-in-
hibition was time dependent. The addition of 500 mM ADMA
produced a signiﬁcant decrease at all time points (an average of
87%). Overall the self-inhibition data suggests the evidence of in-
ﬂux mechanisms. The fact that the concentration of [3H]ADMA
used was more than 10 times less than the lowest concentration of
added unlabelled ADMA and not greatly affected by the ADMA
additions until later time points, suggests that the transporter
being used has a low afﬁnity for ADMA and requires a high con-
centration of unlabelled molecule to demonstrate inﬂux action.
The results from the addition of 100 mM L-arginine show a
slight decrease in accumulation at later time points, despite being
at a concentration more than 2000 times greater than [3H]ADMA.
[3H]ADMA accumulation was decreased with the addition of
20 mM L-homoarginine or the addition of the NAA leucine at the
human physiological plasma concentration (Psychogios et al.,
2011). This ﬁnding suggests that multiple inﬂux transporters are at
work and that inﬂux transport systems separate from system yþ
could also be transporting ADMA as system yþ is insensitive to
leucine (Rotmann et al., 2007). The most likely candidates are yþL
and b0,þ proteins, which have afﬁnities for both CAA and NAAs in
the presence of Naþ ions (O'kane et al., 2006; Rotmann et al.,
2007). Both proteins have been demonstrated at mRNA level in
hCMEC/D3s cells (Carl et al., 2010).
Based on all these data, we conclude that physiological and
pathophysiological extracellular concentrations of ADMA do not
compete signiﬁcantly with L-arginine for entry to cerebral en-
dothelial cells, and that ADMA may use additional transport me-
chanisms to enter the endothelial cell.
To investigate the effects of ADMA on BBB permeability, we
used an assay where hCMEC/D3 cells were grown to conﬂuence on
ﬁlters and were incubated for 24 h with a range of ADMA con-
centrations. The Pe values obtained were similar to those pub-
lished with 40–70 kDa FITC-Dextrans for hCMEC/D3 cells (Weksler
et al., 2005; Forster et al., 2008). At ADMA concentrations of
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40 kDa FITC-Dex when compared to untreated controls. These data
are consistent with previous in vitro studies investigating ADMA
and endothelial dysfunction. In one such study, Chen et al. (2011)
used bovine retinal capillary endothelial cells in a permeability
model, and incubated the cells with 100 mM ADMA for 24 h and
observed an increase in permeability to the paracellular marker,
44 kDa horseradish peroxidise, and a reduced expression of tight
junction protein, occludin. In a study by Wojciak-Stothard et al.
(2009) porcine pulmonary artery endothelial cells were incubated
with 100 mM ADMA for 24 h. They observed a signiﬁcant increase
in permeability compared to control cells (Wojciak-Stothard et al.,
2009). Recently, these ﬁndings were echoed when ADMA in-
creased the permeability of HUVECs grown on transwell ﬁlters to
40 kDa FITC-Dex and FITC-apelin-13 (MW 2053) in a dose-(25–
200 mM ADMA) and time- (4, 8, 16 and 24 h) dependent manner
(Wang et al., 2011).
Chen et al. (2011) showed that ADMA decreased bovine retinal
endothelial cell proliferation in a dose-dependent manner, but did
not link these effects as a possible explanation behind the ob-
served increase in permeability. They suggested that ADMA in-
duced ROS formation caused this endothelial dysfunction. Cere-
brovasculature (BMECs) are extremely sensitive to oxidative stress
due in part to their high expression of NADPH-oxidase, and this
makes them vulnerable to increased concentrations of ROS (Uttara
et al., 2009; Tripathy et al., 2010). Furthermore, ADMA inhibits the
NADPH-oxidase pathway (Wang et al., 2011). In our study, 24 h
incubations with 100 mM and 500 mM ADMA decreased hCMEC/D3
cell viability, which may explain the permeability increase. How-
ever, the mechanism of this toxicity was not ADMA-induced su-
peroxide formation, as demonstrated by the DHE assay. One way
in which ADMA is believed to induce ROS formation is by eNOS
uncoupling. With this in mind, we conﬁrmed the expression of
eNOS in our cells. The addition of the eNOS inhibitor L-NIO in our
permeability experiments however, did not induce any signiﬁcant
permeability differences. Furthermore, DDAH enzymes metabolise
ADMA and their activity is signiﬁcantly decreased in conditions
associated with increased oxidative stress such as hyperglycaemia
and stroke (Lin et al., 2002; Tain and Baylis, 2007; see Sandoval
and Witt (2008) and Chrissobolis et al. (2011) for review). We
determined that DDAH-1 was expressed in the hCMEC/D3 cells.
Loss of DDAH-1 function in mice has been demonstrated to result
in increased ADMA levels and endothelial dysfunction (Leiper
et al., 2007). In relation to this, it has been demonstrated that mice
aorta and cerebral arterioles over-expressing DDAH-1 are pro-
tected against ADMA-induced endothelial dysfunction using
100 mM ADMA (Dayoub et al., 2008).
Interestingly, Wojciak-Stothard et al. (2009) did not ﬁnd any
evidence of ADMA-induced cytotoxicity or changes in ROS in
porcine pulmonary artery endothelial cells, but instead showed
ADMA-induced cytoskeletal and adherens junction remodelling
via modulation of the small GTPase Rac1. Small GTPases are im-
plicated in the control of microvascular permeability; with Rac1 a
major GTPase required for barrier stabilisation and maintenance
(Spindler et al., 2010). Such cytoskeletal remodelling could induce
cytotoxic effects explaining the reduced cell viability when the
hCMEC/D3s were incubated in high concentrations of ADMA, as
discussed in the literature (Stupack and Cheresh, 2003).
TNF-α and IFN-γ increase BMEC permeability through disrup-
tion of cell-cell junctions (Minagar and Alexander, 2003) via acti-
vation of the transcription factor NFκB (Sandoval and Witt, 2008)
and tyrosine-phosphorylation of adherens junction proteins by
GTPases (Dejana et al., 2008). Their effect on hCMEC/D3 perme-
ability has also been demonstrated (Fletcher et al., 2011) with a
similar increase in permeability to FITC-Dex noted (albeit using
70 kDa FITC-Dex). TNF-α and IFN-γ also lead to cytotoxicity inmouse vascular endothelial cells (Yamaoka et al., 2002). It appears
likely that in our permeability model a combination of these ef-
fects were at work in that the hCMEC/D3 junctional complexes
were altered and cytotoxicity-induced apoptosis of the cells con-
tributed to the increase in permeability.
The results of this study are twofold: ﬁrstly, they demonstrate
that both L-arginine and ADMA appear to use system yþ inﬂux
mechanisms to enter hCMEC/D3 BBB cells, as predicted due to
their close structural similarity and chemical composition. They
also demonstrate that this transporter could be CAT-1, the ex-
pression of which was conﬁrmed in our human BBB model. Other
inﬂux systems such as systems yþL and b0,þ appear to have
smaller roles in L-arginine transport, but may have more im-
portant roles for ADMA inﬂux. Also physiological and pathophy-
siological extracellular concentrations of ADMA do not compete
signiﬁcantly with L-arginine transport into the BBB via system yþ .
Secondly, the data from our study show that ADMA is able to in-
crease paracellular permeability in human BBB cells. Although it
was high ADMA concentrations that induced these permeability
increases, that does not rule out the role of more clinically relevant
concentrations in vivo, especially considering the sensitivity of
intracellular DDAH enzymes to oxidative stress which can be in-
duced from several sources during various disease states. ADMA
has been demonstrated to induce endothelial dysfunction that
could have serious implications in brain and cerebrovasculature
pathologies, as well as on the integrity of the BBB itself. Conse-
quently, ADMA is an interesting therapeutic target in neuro-in-
ﬂammatory diseases. The fact that our BBB model expressed both
eNOS and DDAH-1 makes it a good human in vitro BBB model to
study the effects of ADMA and NO inhibition now and in future
studies.4. Experimental procedure
4.1. Materials
Tritium labelled L-arginine was purchased from American
Radiolabelled Chemicals, Inc., MO, US and had a speciﬁc activity of
43 Ci/mmol. [14C]sucrose was purchased from Moravek Biochem-
icals and had a speciﬁc activity of 4980 mCi/mmol. [3H]ADMA was
custom radiolabelled by GE Healthcare, Amersham, UK and had a
speciﬁc activity of 8 Ci/mmol. The Pierce bicinchoninic acid (BCA)
protein assay, enhanced chemiluminescence (ECL) kit and all cul-
ture wear was purchased from Thermo Scientiﬁc, Thermo Scien-
tiﬁc Nunclon, Loughborough, UK. The EGM-2MV BulletKit was
purchased from Lonza, Wokingham, UK. Rat tail collagen type-I,
penicillin-streptomycin, 0.25% Trypsin-EDTA, recombinant human
TNF-α, recombinant human IFN-γ, Dulbecco’s modiﬁed Eagle's
medium without phenol red (DMEM) and Dulbecco's Phosphate-
Buffered Saline without calcium, magnesium and phenol red
(DPBS) were all purchased from Gibco, Invitrogen, Paisley, UK.
Foetal bovine serum (FBS) ‘gold’ was purchased from PAA the Cell
Culture Company, Yeovil, Somerset, UK. Dimethyl sulfoxide
(DMSO), phosphate buffered saline (PBS), 1 M HEPES, (3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), un-
labelled ADMA, unlabelled L-arginine, L-homoarginine, L-leucine,
40 kDa ﬂuorescein isothiocyanate labelled dextran (FITC-Dex),
Triton x-100, Hank's balanced salt solution (HBSS), TGN lysis buffer
components (Tris, NaCl, 10% glycerol, glycerophosphate B, Tween-
20 and NP-40), β-mercaptoethanol, ammonium persulfate (APS),
N,N,N′,N′-tetramethylenediamine (TEMED), 1-octanol, dihy-
droethidium (DHE), hydrocortisone, ascorbic acid, bFGF and
Cornings Transwells polyester membrane inserts (pore size
0.4 mm, membrane diameter 1.12 cm2) were all purchased from
Sigma Aldrich Company Ltd., Poole, UK. N5-(1-Iminoethyl)-L-
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purchased from Cambridge Bioscience Ltd., Cambridge, UK. Pro-
teoblock™ protease inhibitor cocktail and Page Ruler Prestained
10–170 kDa Protein Ladder were purchased from Fermentas Life
Sciences, North Yorkshire, UK. 0.45 mm Immobilon-P poly-
vinylidene ﬂuoride (PVDF) membrane was purchased from Milli-
pore UK Ltd., Watford, UK. Human umbilical vein endothelial cell
lysate was purchased from Santa Cruz Biotechnology, Inc., Cali-
fornia, US. Wild type MCF-7 whole cell lysate was kindly provided
by Dr. Evangelos Pazarentzos of Imperial College London. Rabbit
anti-human SLC7A1/CAT-1 polyclonal primary antibody, goat anti-
human DDAH1 polyclonal primary antibody, mouse anti-human
GAPDH monoclonal primary antibody, rabbit anti-goat HRP con-
jugated polyclonal secondary antibody, goat anti-rabbit HRP con-
jugated polyclonal secondary antibody and rabbit anti-mouse HRP
conjugated polyclonal secondary antibody were all purchased
from Abcam, Cambridge, UK. Rabbit anti-human NOS3/eNOS
polyclonal primary antibody was purchased from BD Biosciences,
VWR, Leicestershire, UK. 4′,6-diamidino-2-phenylindole (DAPI)
was purchased from New England Biolabs, Bristol, UK. Goat anti-
rabbit Alexa Fluor 488 conjugated secondary antibody was pur-
chased from Invitrogen, Paisley, UK. The hCMEC/D3 cell line was
obtained from Professor Pierre O. Couraud (Institut Cochin, Uni-
versité Paris Descartes, CNRS, Paris, France), Professor Babette
Weksler (Weill Medical College of Cornell University, New York,
NY, USA) and Dr Ignacio Romero (The Open University, Depart-
ment of Life Sciences Walton Hall, Milton Keynes, UK). Human
umbilical vein endothelial cell (HUVEC) whole cell lysate was
purchased from Santa Cruz Biotechnology, Inc., California, US.
MCF7 whole cell lysate was a kind gift from Professor Stefan
Grimm (Imperial College London).4.2. Cell culture
The hCMEC/D3s were cultured using EGM-2MV BulletKit as
described previously (Poller et al., 2008; Watson et al., 2012). All
cells used in the experiments were between passage 25 and 35
and cells used in accumulation experiments were seeded at
2.5104 cells/cm2 on 0.1 mg/ml rat tail collagen type-I in HBSS.
Cells grown on transwell ﬁlters (Corning Transwell polyester
membrane inserts, pore size 0.4 mm, membrane area 1.12 cm2)
were seeded at a density of 120,000 cells per ﬁlter (determined
using a haemocytometer). Filters were pre-coated for 2 h with
0.15 mg/ml rat tail collagen type-I in HBSS, before being washed
once with DPBS at 37 °C and then incubated in permeability media
before seeding (0.5 ml in donor well/ﬁlter insert and 1.5 ml in
receiver wells).
The permeability media is a reduced growth factor media
which has been optimised by Professor Pierre Couraud's group
(Institut Cochin, Université Paris Descartes, CNRS, Paris, France)
and follows an established protocol allowing the cells to differ-
entiate and form restrictive tight junctions, restricting paracellular
permeability (Poller et al., 2008; Zougbede et al., 2011). Perme-
ability media consisted of EBM-2 endothelial basal medium from
the Cloneticss EGMs2MV BulletKits with 5% FBS ‘gold’, 1%
penicillin-streptomycin, 1.4 μM hydrocortisone, 5 μg/ml ascorbic
acid, 10 mM HEPES and 1 ng/ml bFGF. The cells were also grown in
an incubator with a saturated humidity at 37 °C in 5% CO2 and 95%
fresh air. Media was changed every 2–3 days and cells used for
experiments were between 8 and 10 days post-seeding.
Protein expression (BCA protein assay) and integrity of plasma
membranes ([14C]sucrose) were monitored to conﬁrm cell viability
and used for correction factors (see details below).4.3. Accumulation assays
For accumulation experiments, cells were grown to 100% con-
ﬂuency (reached at 4 days) in collagen coated 96 well plates and
then left for a further 3 days until experiments (7 days after
seeding). Medium was changed every 2–3 days. Experiments were
performed on conﬂuent monolayers of hCMEC/D3s, grown in the
centre 60 wells of 96 well plates. Medium was aspirated from
wells and replaced with a 200 μl aliquot of [3H]L-arginine or [3H]
ADMA (7 nM or 38 nM, respectively) with [14C]sucrose (972 nM)
as a correction for non-speciﬁc binding, with or without trans-
porter interacting substrates/inhibitors in accumulation assay
buffer (the composition of which has been published previously)
(Watson et al., 2012).
Cells were exposed to the [3H]test molecule/[14C]sucrose/buffer
mix for ﬁve different time periods (1, 2.5, 5, 20 and 30 min) al-
lowing assessment of radiolabelled molecule accumulation in the
cells. The accumulation assays were performed on a temperature-
controlled shaker (THERMOstar, BMG labtech, Offenburg, Ger-
many) at 37 °C and 120 rpm. Once each column of cells had been
exposed for the correct amount of time, the wells were washed
3 times with ice-cold phosphate buffered saline (1 PBS, Gibco,
Invitrogen, UK) to stop transport processes and remove radi-
olabelled test molecules and buffer that had not accumulated in
the cells. The cells were then lysed by adding 200 μl of 1% Triton
x-100 (Sigma, UK) per well for 1 h at 37 °C to liberate any accu-
mulated radiolabelled test molecule and solubilise the cell pro-
teins. 100 μl of each well was then added to scintillation vial along
with 4 ml scintillation ﬂuid (Optiphase Hisafe 2, PerkinElmer, UK)
added and samples counted on a Tricarb 2900TR liquid scintilla-
tion counter (μl/mg). The remaining 100 μl in each well was used
in a BCA™ protein assay, using bovine serum albumin as stan-
dards, and protein concentration measured spectro-
photometrically on a Labsystems Multiscan reader with Ascent
software. Total accumulation of [3H]test molecule in the cells was
expressed as a volume of distribution (Vd). Vd is derived from the
ratio of dpm/mg protein in the lysate to dpm/μl of the accumu-
lation buffer. The Vd values for [3H]test molecule were corrected
with the Vd values for [14C]sucrose which is a marker of non-
speciﬁc binding and extracellular space.
4.4. Transporter inhibition assays
For [3H]L-arginine self-inhibition experiments, (which provide
evidence of saturable mechanisms), 100 μM unlabelled L-arginine
(a similar concentration to that present in human plasma) was
added to the accumulation assay buffer along with the [3H]L-ar-
ginine and [14C]sucrose. In a separate experiments, the system yþ
competitive substrate L-homoarginine (20 mM) and L-leucine
(100 μM) were individually added to the accumulation assay
buffer to investigate the role of system yþ and system yþL
transporters on the transport of L-arginine.
In a separate series of accumulation experiments, the effects of
a range of ADMA concentrations on [3H]L-arginine accumulation
were also assessed. The physiological plasma concentration of
0.5 μM, the pathophysiological plasma concentration of 3 μM and
the supraphysiological concentration of 500 μM (as an extreme
reference point) were added separately to the accumulation buffer
alongside [3H]L-arginine and [14C]sucrose (Teerlink et al., 2009).
For [3H]ADMA investigations, evidence for inﬂux transport
activity was assessed by self-inhibition studies using 0.5 μM, 3 μM
and 500 μM unlabelled ADMA alongside [3H]ADMA and [14C]su-
crose in the accumulation buffer. The inﬂuence of 100 μM un-
labelled L-arginine, 100 μM L-leucine and 20 mM L-homoarginine
were also separately investigated as with [3H]L-arginine.
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To gain an indication of the lipophilicity of the study molecules
[3H]ADMA and [3H]L-arginine, an OSPC was performed using
0.037 MBq (1 μCi) of each molecules in 1 ml of saline as described
previously (Sanderson et al., 2008). The OSPC of [14C]sucrose has
been previously published by our group (Jeganathan et al., 2011).
All OSPC measurements were performed in triplicate.
4.6. Permeability assay
To investigate the effect of ADMA on the integrity of the
hCMEC/D3s, the paracellular permeability was investigated using
permeability assays on conﬂuent monolayers of hCMEC/D3s
grown on 12 well plate transwell ﬁlter inserts.
At 8–10 days post seeding, the TEER of the monolayers on the
ﬁlters was measured as described previously (Patabendige et al.,
2012), at least 4 h before the assay. Filters with TEERs less than the
published hCMEC/D3 TEER values were not used for the perme-
ability assays (Poller et al., 2008; Fletcher et al., 2011). Permeability
media was replaced 24 h before the assay in both the insert
(0.5 ml) and donor wells (1.5 ml) with fresh media containing one
of the following concentrations: 0.5 mM ADMA, 3 mM ADMA, 1 mM
ADMA, 100 mM ADMA or 500 mM ADMA. In a separate series of
experiments, media was added to the cells for 24 h containing
either L-NIO (a non-selective inhibitor of NOS isoforms,) at a
concentration of 5 mM (which is within the 3.9 mM Ki range of
eNOS) (Rees et al., 1990), or 5 ng/ml recombinant human TNF-α
with 5 ng/ml recombinant human IFN-γ, which have been show to
increase brain microvascular endothelial cell (BMEC) permeability
(Minagar and Alexander, 2003; Sandoval and Witt, 2008; Dejana
et al., 2008).
On the day of the experiment, this media was removed from
the transwell ﬁlter insert and the donor well, and 1.5 ml pre-
warmed (to 37 °C) DMEM (without phenol red)þ2% FBS was ad-
ded to the wells of fresh 12 well plates. 40 kDa FITC-Dex was di-
luted to 2 mg/ml in a separate vial of DMEM þ2% FBS assay media
and used as a BBB paracellular marker for the assay (Hoffmann
et al., 2011) by adding 0.5 ml of it to the transwell ﬁlter insert only.
The ﬁlter was then moved into a new donor well on ﬂat bottom
12 well plates (containing DMEM þ2% FBS) at 10-min intervals for
60 min. The ﬂuorescence in each well of 12 well plate was then
measured in a FlexStations 3 Bench top Multi-Mode Microplate
ﬂuorescent plate reader at an excitation wavelength of 485 nm
and emission wavelength of 530 nm, using SoftMaxs Pro Micro-
plate Data Acquisition & Analysis software.
Permeability of FITC-Dex during the assay was determined as
permeability coefﬁcients (Pe) which take into account the relation
between the permeability of the monolayer and the permeability
of empty ﬁlter pre-coated with rat tail collagen type 1 (without
cells). These calculations are based on work by Dehouck et al.
(1992) and Cecchelli et al. (1999), and have been used in sub-
sequent hCMEC/D3 publications (Weksler et al., 2005; Poller et al.,
2008; Tai et al., 2009).
4.7. Detection of ROS formation
hMEC/D3 cells were plated into collagen-coated 24 well plates
and grown for 3 days. Cells were treated with either media alone
(control) or media containing ADMA (0.5, 3, 10, 100 and 500 mM)
or 300 mM hydrogen peroxide (H2O2) as a positive control for 24 h.
At the end of the incubation time, media was removed and cells
were incubated in 10 mM of the ﬂuorescent probe DHE, which
detects intracellular O2. production (D'agostino et al., 2007) in
PBS for 30 min at 37 °C. Cells were washed in PBS and ﬁxed using
freshly prepared 4% paraformaldehyde. After ﬁxation, cells werewashed and stored in PBS at 4 °C for 3–5 days until ﬂuorescent
analysis was performed on a BioTek Synergy HT multi-mode mi-
croplate reader using 530 nm/590 nm excitation and emission
ﬁlters.
4.8. MTT assay
The cytotoxic effects of all the test molecules used in this study
were assessed on conﬂuent monolayers of cells in 96 well plates
using an MTT assay described previously (Watson et al., 2012).
Absorbance values were corrected by protein content (determined
using a BCA assay) and expressed as percentage viability compared
to control untreated cells.
4.9. DDAH-1, eNOS and CAT-1 expression studies
To investigate the expression of eNOS and DDAH-1 in the
hCMEC/D3s, SDS-PAGE and Western blotting (WB) were per-
formed on whole cell lysates, prepared in TGN lysis buffer as de-
scribed previously (Watson et al., 2012). Brieﬂy, lysates were
prepared from cells grown for 8 days in permeability medium and
30 μg of each lysate was loaded per well on a 10% SDS-PAGE gel.
Following electrophoresis, proteins were transferred using semi-
dry transfer onto methanol activated Immobilon-P PVDF mem-
branes (0.45 mM pore size), blocked for 2 h at RT in PBS-Tween
(PBS-T) with 5% milk powder and incubated overnight at 4 °C with
goat anti-human DDAH-1 primary antibody at a dilution of 0.2 μg/
ml PBS-T with 0.5% BSA, or Rabbit anti-human NOS III/eNOS pri-
mary antibody, used at a dilution of 1:2000 in PBS-T and 0.5% BSA.
Membranes were then washed 3 with PBS-T and incubated for
1 h at RT with rabbit anti-goat HRP conjugated secondary antibody
was used at a dilution of 1:2500 in PBS-T with 0.5% BSA for che-
miluminescence detection of DDAH-1 and goat anti-rabbit HRP
conjugated secondary antibody was used at a dilution of 1:5000 in
PBS-T with 0.5% BSA for chemiluminescence detection of eNOS.
GAPDH was probed as a loading control using mouse anti-human
primary antibody at 1:2000 in PBS-T with 0.5% BSA, and rabbit
anti-mouse HRP conjugated secondary at 1:2000 in PBS-T with
0.5% BSA was used for chemiluminescence. For eNOS and DDAH-1
expression, and HUVEC whole cell lysate in RIPA buffer was used
as a positive control (Murakami et al., 2006; Zhang et al., 2011).
The expression of CAT-1 was determined by SDS-PAGE, WB,
and immunoﬂuorescence (IF) with confocal microscopy. For SDS-
PAGE and WB, the procedure above was used and immobilised
proteins probed with rabbit anti-human CAT-1 primary antibody
at a dilution of 1:250 in PBS-T and 0.5% BSA. Goat anti-rabbit HRP
conjugated secondary antibody was used at a dilution of 1:5000
for chemiluminescence detection of CAT-1. Whole wild-type MCF7
cell lysate, prepared in TGN lysis buffer, acted as positive controls
for this transporter (Abdelmagid et al., 2011).
IF of CAT-1 was performed on hCMEC/D3s grown on rat tail
collagen type 1 coated sterile glass coverslips using a previously
described protocol (Watson et al., 2012). Goat anti-rabbit Alexa
Fluor 488 conjugated secondary antibody diluted at 1:200 in PBS
was used to stain CAT-1 bound primary antibody used at a dilution
of 1:200 in PBS-T overnight on the ﬁxed hCMEC/D3s. 0.1 mg/ml
DAPI was used to stain cell nuclei before mounting. Slides were
viewed with a Zeiss LSM710 confocal microscope and image
analysis software Zen 2009 at 63x (Zeiss, Germany).
4.10. Statistical analysis
Comparisons were made between control and test plates of
cells and differences at po0.05 considered signiﬁcant. Multiple-
time accumulation data were analysed by Two Way Repeated
Measures ANOVA tests and Holm-Sidak posthoc tests. MTT assay
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controls using One Way ANOVA and Bonferonni post-hoc tests. All
data were analysed using Sigma Plot version 11.0 software (SPSS
Science Software UK Ltd., Birmingham UK) and expressed as
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